384-well Electrophysiology - Accelerating Ion Channel Characterization and New Drug Candidate Identification
Webinar Date: November 3, 2016
Employing the Syncropatch 384PE to characterize human disease associated ion channel mutations and identify new candidate therapeutics agents.
The ever increasing pressure to accelerate drug development by reducing the time to establish strong biological rationale, implement robust discovery programs while maintaining high data quality, has resulted in the development of new technologies. In the world of ion channel focused drug development, this has involved the development and evolution of high throughput electrophysiology platforms that maintain the high fidelity of the "gold standard" patch clamp platform while greatly increasing throughput. The 384 well planar patch clamp platform Syncropatch 384PE from Nanion is one of the leaders in this field and has opened up opportunities to accelerate both ion channel characterization and drug discovery and development. This webinar will focus on the application of the Syncropatch 384PE to enable a better understanding of how human disease associated mutations alter ion channel function, and to facilitate drug candidate characterization. Specifically, high-throughput functional annotation of human ion channel variants associated with excitation disorders will be described along with the use of the Syncropatch 384PE to measure subtype selective activation of Kv7 potassium channels as well as inhibition of voltage-gated sodium channels like Nav1.7, Nav1.1, and Nav1.5.
Webinar attendees will learn about:
- Characterization of functional changes in voltage-dependent sodium and potassium channel properties associated with human disease-causing mutations.
- Use of Syncropatch 384PE for identifying and characterizing subtype selective modulators of voltage-gated sodium and potassium channels
Discussions lead by:
Professor Alfred George
Chair, Department of Pharmacology, Director, Center for Pharmacogenomics, Magerstadt Professor of Pharmacology. Northwestern University Feinberg School of Medicine
Matt Fuller, Ph.D.
Senior Scientist, Icagen